Company Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.
The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio.
In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache.
Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis.
It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
| Country | United States |
| Founded | 1876 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 43,000 |
| CEO | David A. Ricks |
Contact Details
Address: Lilly Corporate Ctr, Drop Code 1094 Indianapolis, Indiana 46285 United States | |
| Phone | (317) 276-2000 |
| Website | lilly.com |
Stock Details
| Ticker Symbol | LLY |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000059478 |
| CUSIP Number | 532457108 |
| ISIN Number | US5324571083 |
| Employer ID | 35-0470950 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David A. Ricks | Chairman, Chief Executive Officer and President |
| Anat Ashkenazi | Executive Vice President and Chief Financial Officer |
| Dr. Daniel M. Skovronsky M.D., Ph.D. | EVice President, Chief Scientific Officer and President of Lilly Research Laboratories and Lilly immunology |
| Anat Hakim J.D. | Executive Vice President, General Counsel and Secretary |
| Jacob S. Van Naarden | Executive Vice President and President of Loxo |
| Donald A. Zakrowski | Senior Vice President of Finance and Chief Accounting Officer |
| Diogo Rau | Executive Vice President and Chief Information and Digital Officer |
| Alonzo Weems | Executive Vice President of Enterprise Risk Management and Chief Ethics and Compliance Officer |
| Eric Dozier | Executive Vice President of Human Resources and Diversity |
| Jeffrey N. Simmons | Senior Vice President and President of Elanco Animal Health |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 11, 2024 | PX14A6G | Notice of exempt solicitation submitted by non-management |
| Apr 4, 2024 | PX14A6G | Notice of exempt solicitation submitted by non-management |
| Mar 28, 2024 | PX14A6G | Notice of exempt solicitation submitted by non-management |
| Mar 28, 2024 | PX14A6G | Notice of exempt solicitation submitted by non-management |
| Mar 28, 2024 | PX14A6G | Notice of exempt solicitation submitted by non-management |
| Mar 22, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 22, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 11, 2024 | 144 | Filing |
| Mar 8, 2024 | PRE 14A | Other preliminary proxy statements |
| Feb 21, 2024 | 10-K | Annual Report |